Last checked at 9 Feb 2015 07:00
For immediate release
9 February 2015
Carclo plc
("Carclo" or the "Group")
Notice of General Meeting
Following the announcement made on 5 February 2015 as part of the interim management statement, Carclo plc (the Company) announces that it has today issued a circular to shareholders to convene a general meeting of the Company to be held at 3.30 p.m. on 25 February 2015 at the Company's registered office, to seek shareholder approval for the cancellation of the Company's share premium account and capital redemption reserve.
The board of directors of the Company is recommending the cancellations (which, if shareholder approval is obtained, will also need to be confirmed by the High Court of Justice in England and Wales) in order to augment the Company's distributable reserves and therefore allow the Company to have access to sufficient distributable reserves to, amongst other matters, enable future dividends to be paid as and when the Board considers it appropriate.
The reasons for, background to, and a summary of the court process relating to the cancellations are set out in full in the circular and a copy of the circular is available on the Company's web site at www.carclo-plc.com
- ENDS -
Enquiries:
Carclo plc |
| 01924 268040 |
Chris Malley, Chief Executive |
|
|
Robert Brooksbank, Finance Director |
|
|
|
|
|
Peel Hunt LLP |
| 0207 418 8900 |
Justin Jones |
|
|
Jock Maxwell Macdonald |
|
|
Mike Bell |
|
|
N+1 Singer Shaun Dobson Richard Lindley
|
|
0207 496 3000 |
Weber Shandwick Nick Oborne Tom Jenkins |
| 0207 067 0000 |
Notes to editors
Carclo plc is a public company whose shares are quoted on the London Stock Exchange.
Carclo's strategy is to develop and expand its key manufacturing assets where there remain significant further opportunities to drive value. To enhance profit margins the group has been investing in new technologies.
Approximately three fifths of revenues are currently derived from the supply of fine tolerance, injection moulded plastic components, mainly for medical products. The balance of revenue is derived mainly from the design and supply of specialised injection moulded LED based lighting systems to the low volume premium automotive industry.